1.黄颂敏.糖尿病肾病//谌贻璞.肾内科学.北京：人民卫生出版社，2008，70-86.

2. Shan G，Yang W，Xiao J，et al. Prevalence of diabetes among men and women in China.N Engl J Med，2010，362 （12）：1090-1101.

3. Xu Y，Wang L，He J，et al.Prevalence and control of diabetes in Chinese adults.JAMA，2013，310（9）：948-959.

4. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease.Am J Kidney Dis，2007，49：S1-S180.

5. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD：2012 update.Am J Kidney Dis，2012，60（5）：850-886.

6. American Diabetes Association.Standards of medical care in diabetes-2013.Diabetes Care，2013，36（1）：S11-S66.

7. Tervaert TW，Mooyaart AL，Amann K，et al. Pathologic classification of diabetic nephropathy.J Am Soc Nephrol，2010，21（4）：556-563.

8. Kanwar YS，Sun L，Xie P，et al.A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu Rev Pathol，2011，6（1）：395-423.

9. Stitt-Cavanagh E，MacLeod L，Kennedy C.The podocyte in diabetic kidney disease.Scientific World Journal，2009，9：1127-1139.

10. Weil EJ，Lemley KV，Mason CC，et al.Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy.Kidney Int，2012，82（9）：1010-1017.

11. Gilbert RE.The endothelium in diabetic nephropathy.Curr Atheroscler Rep，2014，16（5）：410.

12. Habib SL.Diabetes and renal tubular cell apoptosis.World J Diabetes，2013，4（2）：27-30.

13. Lim AK，Tesch GH.Inflammation in diabetic nephropathy.Mediators Inflamm，2012，2012：146-154.

14. Wada J，Makino H.Inflammation and the pathogenesis of diabetic nephropathy.Clin Sci，2013，124（3）：139-152.

15.杨玉玺，黄颂敏，颜骁勇，等.糖尿病肾病模型中NF-κB与甘露聚糖结合凝集素途径补体激活的关系.四川大学学报（医学版），2011，42（4）：490-493.

16.邱红渝，樊文星，黄颂敏，等.高糖对人肾小球内皮细胞膜表面多糖-蛋白复合物厚度及核心蛋白Syndecan-1和Glypican-1表达的影响.四川大学学报（医学版），2010，41（6）：980-985.

17. Mooyaart AL，Valk EJ，van Es LA，et al.Genetic associations in diabetic nephropathy：a meta-analysis.Diabetologia，2011，54（3）：544-553.

18. Kato M，Natarajan R.microRNA cascade in diabetic kidney disease：Big impact initiated by a small RNA.Cell Cycle，2009，8（22）：3613-3614.

19. Khella HW，Bakhet M，Lichner Z，et al.MicroRNAs in kidney disease：an emerging understanding.Am J Kidney Dis，2013，61（5）：798-808.

20. Smith AC，Burton JO.Exercise in kidney disease and diabetes：time for action.J Ren Care.2012，38 Suppl 1：52-58.

21.α酮酸制剂在肾内科应用专家协作组.慢性肾脏病蛋白营养治疗共识.中华肾脏病杂志，2005，21（7）：421-424.

22. Haimoto H，Sasakabe T，Umegaki H，et al.Reduction in urinary albumin excretion with a moderate low-carbohydrate diet in patients with type 2 diabetes：a 12-month intervention.Diabetes Metab Syndr Obes，2012，5：283-291.

23.中华医学会内分泌学分会.中国成人2型糖尿病HbA1c控制目标的专家共识.中国医学前沿杂志（电子版），2011，3（4）：73-77.

24.中国医师协会内分泌代谢科医师分会.2型糖尿病合并慢性肾脏病患者口服降糖药应用原则的中国专家共识.中国糖尿病杂志，2013，21（10）：865-870.

25. Mancia G，Fagard R，Narkiewicz K，et al.2013 ESH/ESC Guidelines for the management of arterial hypertension：The Task Force for the management of arterial hypertension of the European Society of Hypertension（ESH）and of the European Society of Cardiology（ESC）.J Hypertens，2013，31（7）：1281-1357.

26. James PA，Oparil S，Carter BL，et al.2014 evidence-based guideline for the management of high blood pressure in adults：report from the panel members appointed to the Eighth Joint National Committee（JNC 8）.JAMA，2014，311（5）：507-520.

27. Kidney Disease：Improving Global Outcomes（KDIGO）Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease.Kidney Int Suppl，2012，2：337-414.

28. Mancia G，Laurent S，Agabiti-Rosei E，et al.Reappraisal of European guidelines on hypertension management：a European Society of Hypertension Task Force document.J Hypertens.2009，27（11）：2121-2158.

29. Fernandez Juarez G，Luño J，Barrio V，et al；PRONEDI study group.Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy：a randomized trial.Am J Kidney Dis，2013，61（2）：211-218.

30. Fried LF，Emanuele N，Zhang JH，et al；VA NEPHROND investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy.N Engl J Med，2013，369（20）：1892-1903.

31. Morello CM.Pharmacokinetics and pharmacodynamics of insulin analogs in special populations with type 2 diabetes mellitus.Int J Gen Med，2011，4：827-835.

32. Weinhandl ED，Foley RN，Gilbertson DT，et al.Propensity-matched mortality comparison of incident hemodialysis and peritoneal dialysis patients.J Am Soc Nephrol，2010，21（3）：499-506.

33. Chang JH，Sung JY，Ahn SY，et al.Hemodialysis leads to better survival in patients with diabetes or high comorbidity，compared to peritoneal dialysis.Tohoku J Exp Med，2013，229（4）：271-277.

34. Slinin Y，Ishani A，Rector T，et al.Management of hyperglycemia，dyslipidemia，and albuminuria in patients with diabetes and CKD：a systematic review for a KDOQI clinical practice guideline.Am J Kidney Dis，2012，60（5）：747-769.